Upcoming US legislation, known as the 21st Century Cures Act, will incorporate more of the patient experience into drug development. There will be a focus on structured collection of data from patients about the personal [...]
Expanded Access Programs (EAPs), also known as Managed Access Programs, help sick patients gain access to drugs that are not available through traditional access routes. These can be drugs that are still in development, in [...]
For some sick patients, receiving medication through an Expanded Access Program (EAP), also known as managed access, compassionate use, named patient, etc., is the only viable treatment option left. These programs allow the patients to gain access to investigational new drugs which are still in the clinical trial phase and are not, yet, licensed for use ...Read More
Clinical trials have been conducted for decades, and, although people might not know the intricate ins and outs of how trials actually work, most people have at least heard of them. In comparison, Expanded Access, also known as Managed Access, Compassionate Use, Named Patient, etc. is a relatively new phenomenon. ...Read More
WEP Clinical (WEP) is pleased to announce our partnership with Pharming Group N.V. ("Pharming" EURONEXT Amsterdam: PHARM/Nasdaq: PHAR), a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and [...]
WEP Clinical Inc. (WEP) is pleased to announce that it has partnered with Sellas Life Sciences Group, Inc. (“Sellas”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for various cancer [...]
WEP Clinical (WEP), a specialist services company that works with sponsors to help patients and physicians gain early access to medicines when no other treatment options are available, has appointed Karl Challender as the [...]
WEP Clinical (WEP) today announced a partnership with Horizon Therapeutics plc (Horizon) to make a Named Patient Use (NPU) Program available for UPLIZNA. The UPLIZNA NPU Program is for adult patients who are AQP4-IgG+ [...]
WEP Group Holdings Limited (WEP Clinical) is pleased to announce the closure of an investment in the company made by The Jordan Company, L.P. (TJC), a middle-market private equity firm. Under the terms of [...]
WEP Clinical LTD (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available, has partnered with biopharmaceutical [...]
